INBRX-109
Phase 2Small molecule
INBRX-109 is one of 22 small molecule programs targeting Chondrosarcoma. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Chondrosarcoma
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Tibsovo
SServier
Phase 3
Votrient
NovartisPhase 2
Erivedge
RochePhase 2
Neulasta
AmgenPhase 2
Gleevec
NovartisPhase 2
Tecentriq
RochePhase 2
Astplayer
AAstex Pharmaceuticals, Inc.
Phase 2
Alimta
GGynecologic Oncology Group
Phase 2
Taxotere
AAvyxa
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for INBRX-109. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IInhibrx Biosciences, Inc